Related Experiment Video
Updated: May 14, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy
1Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX, USA.
Abstract:
Targeted therapeutics are potential therapeutic agents because of their selectivity and efficacy against tumors resistant to conventional therapy. The goal of this study was to determine the comparative activity of monovalent, engineered anti-Her2/neu immunotoxins fused to recombinant gelonin (rGel) to the activity of bivalent IgG-containing immunoconjugates. Utilizing Herceptin and its derived humanized single-chain antibody (single-chain fragment variable, designated 4D5), we generated bivalent chemical Herceptin/rGel conjugate, and the corresponding monovalent recombinant immunotoxins in two orientations, 4D5/rGel and rGel/4D5. All the constructs showed similar affinity to Her2/neu-overexpressing cancer cells, but significantly different antitumor activities. The rGel/4D5 orientation construct and Herceptin/rGel conjugate were superior to 4D5/rGel construct in in vitro and in vivo efficacy. The enhanced activity was attributed to improved intracellular toxin uptake into target cells and efficient downregulation of Her2/neu-related signaling pathways. The Her2/neu-targeted immunotoxins effectively targeted cells with Her2/neu expression level >1.5 × 10(5) sites per cell. Cells resistant to Herceptin or chemotherapeutic agents were not cross-resistant to rGel-based immunotoxins. Against SK-OV-3 tumor xenografts, the rGel/4D5 construct with excellent tumor penetration showed impressive tumor inhibition. Although Herceptin/rGel conjugate demonstrated comparatively longer serum half-life, the in vivo efficacy of the conjugate was similar to the rGel/4D5 fusion. These comparative studies demonstrate that the monovalent, engineered rGel/4D5 construct displayed comparable in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate. Immunotoxin orientation can significantly impact the overall functionality and performance of these agents. The recombinant rGel/4D5 construct with excellent tumor penetration and rapid blood clearance may reduce the unwanted toxicity when administrating to patients, and warrants consideration for further clinical evaluation.
Insights
Engineered immunotoxins targeting Her2/neu show potent antitumor activity. Monovalent constructs like rGel/4D5 offer comparable efficacy to bivalent conjugates, suggesting potential for reduced toxicity in cancer therapy.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Targeted therapeutics offer selective efficacy against resistant tumors.
- Anti-Her2/neu immunotoxins are investigated for cancer treatment.
Purpose of the Study:
- Compare the antitumor activity of monovalent anti-Her2/neu immunotoxins (rGel) with bivalent immunoconjugates.
- Evaluate the impact of immunotoxin orientation on efficacy.
Main Methods:
- Generated monovalent (4D5/rGel, rGel/4D5) and bivalent (Herceptin/rGel) immunoconjugates.
- Assessed in vitro and in vivo antitumor activity against Her2/neu-overexpressing cells and xenografts.
- Analyzed cellular uptake and signaling pathway modulation.
Main Results:
- All constructs exhibited similar affinity for Her2/neu-positive cells.
- rGel/4D5 and Herceptin/rGel showed superior in vitro and in vivo efficacy compared to 4D5/rGel.
- rGel-based immunotoxins demonstrated efficacy against Herceptin-resistant cells.
- rGel/4D5 exhibited excellent tumor penetration and inhibition of SK-OV-3 xenografts.
Conclusions:
- Monovalent rGel/4D5 immunotoxin demonstrates comparable antitumor efficacy to bivalent Herceptin/rGel conjugate.
- Immunotoxin orientation significantly influences functionality.
- The rGel/4D5 construct shows promise for clinical evaluation due to efficacy and potential for reduced toxicity.
